Today, the FDA published a Federal Register (FR) notice ( here ) announcing a preliminary decision regarding three bulk drug substances that it has evaluated and is proposing not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide. The notice further states that the FDA will consider comments submitted to the docket until June 30, 2026 prior to making a final decision
Dr Gary Deed, Chair of RACGP Specific Interests Diabetes, said the trial is an interesting study
Doses are titrated based on patient tolerance and provider protocol
It helps you feel full, slows down digestion, and helps control blood sugar resulting in: Making you feel full sooner Keeping you full longer Reducing hunger and snacking Helping your body release insulin when you eat keeping your blood sugar stable Semaglutide Semaglutide works on the GLP-1 only by acting like a natural hormone that helps control your appetite and blood sugar
Journal of Investigative Dermatology Jiang, Y., & Wang, D